Regional Burn Conferences Present 12 Data Presentations of the RECELL® System by Leading Burn Surgeons


Receive instant alerts for news on your actions. Claim your 1-week free trial for StreetInsider Premium here.

VALENCIA, California and MELBOURNE, Australia, October 28, 2021 (GLOBE NEWSWIRE) – AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that develops and markets a technology platform that enables skin restoration autologous care for multiple unmet needs, today announced that 12 data presentations from the RECELL® System will be shared at the upcoming South and Northeast Regional Burn Conferences. The presentations will highlight a wide range of data including pediatric results, cost-effectiveness and multiple case studies using the RECELL system. The Southern Region Burns Conference will be held November 4-7 in New Orleans while the Northeast Region Burns Conference will be held November 12-13 in Burlington, Vermont.

“The data provided by physicians and presented at these two conferences underscores the depth and breadth of use of the RECELL system among severe burn surgeons in the United States,” said Dr. Mike Perry, CEO of AVITA Medical. “The patient success stories that we hear regularly from burn specialists continue to fuel the enthusiasm of our teams and their continued evaluation of the RECELL System platform for the treatment of new indications, such as vitiligo and soft tissue damage.

RECELL System Presentations at Southern Burns Conference

  • Variations in length of stay in pediatrics: evaluation of cases and actual data of the use of an autologous cell collection device against standard of care in the treatment of burns requiring hospitalization in a hospital setting. Author: N. Kopari, Children’s Hospital, New Orleans
  • Simplify the algorithm of the treatment route and the number of operations: use of ASCS for thermal burns. Author: W. Hickerson, Memphis, Tennessee
  • “Minimally invasive” skin graft with enzymatic debridement and spraying of autologous skin cells. Authors: G Gaweda, S Kahn, MUSC Department of Burn Surgery
  • Histological changes in skin biopsies after suspension of autologous skin cells. Author: Laurent, University Medical Center and LSU, New Orleans
  • Results for 43 burns on hands treated with 2: 1 mesh and epidermal autografts when donor sites are abundant. Author: Yoo, University Medical Center and LSU, New Orleans
  • Early postoperative mobilization after treatment of burns with suspension of autologous skin cells. Authors: Kelly, S. Kahn, MUSC Department of Burn Surgery
  • The use of autologous skin suspension in thermal scalp injury: a case report. Authors: Yoo, University Medical Center and LSU, New Orleans
  • An assessment of the cost-effectiveness of real-world data from the use of an autologous cell harvesting device versus standard of care in the treatment of burns requiring hospitalization. Author: Carson, Loyola Burn Center Chicago
  • Implementation of an autologous skin cell suspension in an ABA burn center: a comparison of operative efficiency using RECELL versus standard split thickness autograft. Author: D. Bell, University of Rochester Medical Center
  • Results of using cultured epidermal autograft (CEA) and autologous spray cell suspension (ASCS) in addition to Split. Authors: R. De Ayala, Grady Hospital

RECELL System Presentations at Northeast Region Burn Conference

  • Optimal donor sites for the autologous cell suspension device (RECELL system) in the reconstruction of pediatric burns. Author: B. Temple, St. Christopher’s Hospital for Children, Philadelphia, PA
  • An evaluation of the cost-effectiveness of using an autologous cell harvesting device against standard of care in the treatment of burns requiring hospitalization: L. Rae, Temple Health Burn Center, Philadelphia, PA

For more information on the RECELL system, please visit

ABOUT AVITA MEDICAL, INC.AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs for burns, chronic wounds and aesthetic indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s skin. Medical devices work by preparing RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension made up of the patient’s skin cells needed to regenerate healthy natural epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first US product, the RECELL® System, was approved by the United States Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin ™ cells using a small amount of patient skin, providing a new way to treat severe burns, while dramatically reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn. Compelling data from randomized, controlled clinical trials conducted in major US burn centers and real-world use in more than 10,000 patients worldwide supports the fact that the RECELL system is a significant advance over the current standard of care for burn patients and offers benefits in terms of clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL® Autologous Cell Harvesting Device ( for a complete description of the indications for use and important safety information, including contraindications. , warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL system is registered with the TGA in Australia and has received CE mark approval in Europe. To learn more, visit

CAUTION REGARDING FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements. These forward-looking statements can generally be identified by the use of words such as “anticipate”, “expect”, “intend”, “could”, “could”, “may”, “believe”, “Estimate”, “look ahead”, “forecast”, “objective”, “target”, “project”, “continue”, “prospect”, “direction”, “future”, other words with similar meaning and use of future dates. Forward-looking statements in this press release include, without limitation, statements regarding, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth of our business and our ability to achieve our key strategic, operational and financial objective. Forward-looking statements, by their nature, deal with matters that are, to varying degrees, uncertain. Each forward-looking statement contained in this press release press is subject to risks and uncertainties which could cause actual results to differ materially from those expressed or implied by such statement. The applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; acceptance, approval and use of our products by physicians; failure to obtain the expected benefits from the approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other trade effects, including the effects of industrial, economic or political conditions beyond the control of society. Investors should not place significant reliance on any forward-looking statements contained in this press release. Investors are encouraged to read our publicly available documents for a discussion of these and other risks and uncertainties. The forward-looking statements contained in this press release speak only as of the date of this press release, and we assume no obligation to update or revise any such statements.

This press release has been authorized by the review board of AVITA Medical, Inc.


Main logo

Source: AVITA Medical

Source link

Leave A Reply

Your email address will not be published.